Groups of 110 Fischer 344 rats/sex were fed diisononyl phthalate (DINP) at dietary levels of 0, 0.03, 0.3, and 0.6 wt% for periods up to 2 years. Interim sacrifices of 10 predesignated rats/sex/dose were at 6, 12, and 18 months with surviving animals sacrificed at 24 months. At study termination, survival was in excess of 60% for every group. At the mid or high dose, the following biological effects were noted: slight decreases in food consumption and body weight; slight increase in mortality; a dose-related increase in relative organ weights of liver and kidney; and some slight effects on urinalysis, hematologic, and clinical chemistry parameters. No peroxisome induction was observed in livers of treated rats compared with controls. No clear treatment-related nonneoplastic or neoplastic lesions were found. However, mononuclear cell leukemia (MNCL) and changes known to be associated with an increased incidence of MNCL were seen in the mid-dose and highdose groups. A literature review suggests that MNCL is a common finding in aging F344 rats and that this increased incidence in rats treated with DINP is not relevant to man. A clear no-observedeffect level was demonstrated for all biological end points at a dietary level of 0.03 wt% or approximately 17 mg/kg/day of DINP.
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Diisononyl phthalate (DINP) is an isomeric mixture of diesters of orf/io-phthalic acid and primary aliphatic branched chain alcohols, predominantly in the Q range. DENP is used principally as a polyvinyl chloride plasticizer (Cadogan, 1992) . In an occupational environment, exposure to DINP can occur by inhalation and dermal contact. How-1 Presented in part at the 26th Annual Meeting of the Society of Toxicology in Washington, DC, February 1987. 2 To whom correspondence should be addressed (AWL) at Exxon Biomedical Sciences, Inc., Mettlers Road, CN 2350 , East Millstone, NJ 08875-2350 3 Present address: ENSR Consulting and Engineering, 4413 West Laporte Ave., Fort Collins, CO 80621. 4 Present address: 506 Scarborough Ave., Rehobeth Beach, DE 19971-3023. ever, due to its low vapor pressure, limited water solubility, and limited transdermal penetration , the dose is Limited. In nonoccupational settings, oral exposure to DINP can also occur as the result of ingestion through the use of DINP as an indirect food additive (MAFF, 1987) . However, exposure to DINP by all routes is believed to be low, well below 1 mg/kg/day.
The toxicity of DLNP has been relatively well studied in animals. It possesses a low order of acute and subchronic toxicity in rats and dogs (Bird et al., 1986; EBSI, 1971a,b; Krauskopf, 1973; Lington et al., 1993) . DINP is nongenotoxic in a battery of bacterial and mammalian cell assays (CMA, 1986; EBSI, 1996a,b; Omori, 1976; Zeiger et al., 1985) .
As with other phthalates, orally administered DLNP is readily hydrolyzed to the corresponding monoester (MLNP) and corresponding alcohol; these forms can be absorbed and metabolized to yield a number of oxidized metabolites (ElHawari et al., 1985; Lington et al., 1985) . In subchronic oral studies, DINP at high dietary levels (sslOOO mg/kg/day) increases liver weight significantly and also increases the number of peroxisomes and the quantity of peroxisomal enzymes in the liver of rats without producing histopathologic changes (Bird et al., 1986; BIBRA, 1985b; Shellenberger et al., 1983) . Studies using rat hepatocyte culture indicate that the monoester, rather than the alcohol, is the active form of DLNP that stimulates peroxisomes (Benford et al., 1986; Rhodes et al., 1984) . A number of other structurally diverse chemicals are known to produce hepatic peroxisome induction in rats and/or mice, but these effects are less evident in other species, including guinea pigs, hamsters, monkeys, marmosets, and man (Ashby et al., 1994) . Indeed, MLNP produced minimal effects on peroxisomal induction in marmoset hepatocytes (Benford et al., 1986) . It has been suggested that chemicals which produce marked and sustained peroxisome proliferation may also produce liver cancer in chronic studies in rats (Reddy and Lalwani, 1983) . If this theory is correct, doses of chemicals which produce minimal or no effect on peroxisome induction would be anticipated not to produce rodent liver tumors and there are data consistent with this view (Ashby et al., 1994) .
As a prelude to conducting a chronic study on DINP, disposition and metabolism studies were conducted in F344 rats using single and repeated oral doses of DINP ranging from 50 to 500 mg/kg (El-Hawari et al., 1985; Lington et al., 1985) . Most of 14 C carboxyl-labeled DINP was eliminated during die first 24 hr in the urine with no evidence of tissue accumulation of labeled DINP. Most of the labeled DINP in the urine was as side-chain oxidation products of the monoester, MINP. The liver, a target organ of DINP, contained major amounts of MINP and oxidation products of the monoester. In addition, a 13-week dietary study was done at doses of 0. 0.1, 0.3, 0.6, 1.0, and 2.0% DINP in the diet (Bird et al., 1986) . The dose selection for the chronic study on DINP was based mainly on the 13-week dietary study on DINP in F344 rats. High dietary doses of DINP (1.0 and 2.0%) produced a decrease in body weight gain which was statistically significant at 2.0% DINP. Liver enlargement and kidney effects were observed at dietary doses of 0.3% and higher with kidney lesions (nephrosis) in male rats increasing with dose. Based on electron microscopy findings, hepatic peroxisome induction was notably increased at 1.0 and 2.0% and a weak increase was also observed at 0.6%. In view of the above, the high dose selected was limited to 0.6% DINP because higher doses of DINP might have jeopardized survival due to kidney lesions (Bucher et al., 1996; Ettlin et al., 1994) . The mid dose of 0.3% was selected to produce lesser effects on the liver and kidney. The low dose of 0.03% was selected as an anticipated no-observed-effect level based on 13-week data and pharmacokinetic considerations in F344 rats.
The present study had three primary objectives. The first was to assess the chronic toxicity and oncogenicity of DINP at a dose close to the maximum tolerated dietary dose of 0.6 wt%. The second objective was to determine whether DINP could produce hepatic peroxisome proliferation under chronic exposure conditions. The third objective was to define a no-observed-effect level (NOEL) for DENP under chronic exposure conditions.
METHODS
Test material and treatment. Jayrlex DINP , supplied by Exxon Chemical Co. (Baton Rouge, LA), was greater than 99% DINP by high-pressure liquid chromatography (HPLC) analysis. Isononyl alcohol is a known impurity of DINP.
DINP was added to Purina Certified Rodent Chow 5002 on a fixed weight percentage (w/w) basis and mixed thoroughly to ensure homogeneity. The test diets were prepared on a weekly basis. The stability of DINP in the test diets was demonstrated periodically. Weighed aliquots of feed samples were extracted with n-hexanol, filtered, and analyzed by reverse-phase HPLC. Homogeneity and stability of test chemical in the diets were verified analytically by HPLC. The lower limit of detection, based on 2-g aliquots of feed, was 0.004 wt% DINP. Analysis for uniformity of mixing was conducted on all test material containing batches prepared for use on Weeks 1, 2, 27, and 53 of the study and was determined to be within ±10% of the target concentration.
Animals and husbandry. Young adult Fischer 344 rats from Charles River Breeding Laboratory (Stoneridge, New York) were used. The rats were approximately 6 weeks old at study initiation. The rats were individually housed except during the first week of acclimation. Caging was suspended stainless steel with indirect bedding and water was provided ad libitum by an automatic watering system. The diet was supplied ad libitum with fresh diet presented weekly. Animals were identified by Monel ear tags and corresponding cage identification.
Experimental design and observation. Four hundred and forty rats of each sex were assigned randomly to each of four dose groups, each group consisting of 110 rats/sex. The groups consisted of a control and three treatment groups of DINP at 0.03, 0.3, and 0.6 wt%. Preselected groups of 10 rats/sex/group were scheduled for interim sacrifice after 6, 12, and 18 months on study. The animals remaining on study were sacrificed at 24 months. Clinical laboratory studies were performed on blood and urine specimens collected from the animals scheduled for interim sacrifices and on 20 rats/sex/group sacrificed at termination.
In-life observations. The animals were examined daily for viability. Clinical observations were made weekly for all animals throughout the study for nature, onset, and duration of toxicological signs. Body weight and feed consumption were determined weekly on the same day of the week. A complete gross necropsy that included weighing and preservation of selected organs was conducted on all animals sacrificed at 6, 12, and 18 months and at study termination. Tissues, masses, and gross lesions were also preserved from animals that died spontaneously or were sacrificed in moribund condition during the course of the study.
Clinical determinations. Blood samples were collected from the abdominal aorta after an overnight fast (16 hr). Hematologic measurements and calculations included red blood count (RBC), hematocrit, hemoglobin, leukocyte count (total and differential), mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentrations, platelets, and reticulocyte count. The following clinical chemistry parameters were evaluated: albumin/globulin ratio, albumin, blood urea nitrogen, calcium, cholesterol, creatinine, electrolytes (Na + , K + , CP), globulin, glucose, serum glutamic oxaloacetic transaminase (SCOT or AST), serum glutamic pyruvic transaminase (SGPT or ALT), serum osmolality, total bilimbin, total protein, and triglycerides.
Quantitative urine assays consisted of urine volume, glucose, protein, creatinine, renal epithelial cell counts (REC), sodium, potassium, and osmolality. Qualitative urine assays consisted of pH, specific gravity, ketones, bilirubin, and occult blood. One week prior to each interim sacrifice and 2 weeks prior to terminal sacrifice, urine samples were collected during a 16-hr period for these qualitative and quantitative analyses. The animals were not fasted during this period.
Pathology. Complete necropsies were performed on all animals. Prior to tissue fixation, the following organs were weighed at the interim and terminal sacrifices: adrenals, brain, heart, kidney, liver, ovaries, spleen, testes, and thyroid/parathyroids.
Tissues were preserved in 10% neutral buffered formalin and processed (paraffin technique) for light microscopic examination. Microscopic examination of hematoxylin-and eosin-stained sections was performed on tissues from all major organs in the high-dose and control groups plus gross lesions and target tissues (liver, kidney) from the mid-and low-dose groups. At study termination, the following tissues were examined by light microscopy: adrenals, aorta, brain, epididymis, esophagus, eyes with optic nerve, femoral muscle with sciatic nerve, Harderian glands, heart, kidneys, large intestines (colon, cecum), liver, lungs (infused with fixative), mammary gland, mesenteric lymph nodes, ovaries, pancreas, pituitary, prostate, rectum, salivary glands, seminal vesicles, skin, small intestines (duodenum, jejunum, ileum), spinal cord (cervical, midthoracic, lumbar), spleen, sternum with marrow, stomach, testes, thyroid/parathyroids, trachea, urinary bladder, uterus, vagina, all gross lesions, and all tissue masses. Only the following tissues from the animals sacrificed at 6, 12, and 18 months were prepared for light microscopic examination: all gross lesions, all tissue masses, epididymides, kidneys, liver, lungs, ovaries, pituitary, spleen, testes, and thyroid. All tissues were examined from animals that died or were sacrificed moribund during the study except when precluded by autolysis.
Morphological examination of liver. Livers of two rats/sex/dose group including controls were examined by electron microscopy for evidence of hepatic peroxisome induction at study termination. The evaluation was conducted in a nonblind manner using an identical protocol as that used in the 13-week dietary study on DINP in F344 rats (Bird et al.. 1987) . Briefly, at necropsy, representative liver specimens from the right lobe were excised, minced, and rapidly fixed by immersion with Kamofsky fixative. These specimens were postfixed in 1% phosphate-buffered osmium tetroxide. Ultratbin sections were stained with uranyl acetate and lead citrate and examined in a Hitachi 12A electron microscope.
Statistical evaluation. Food consumption, body weights, organ weights, relative organ weights, serum chemistry, hematology, and urine chemistry parameters were evaluated by appropriate statistical methods. Bartlett's test of homogeneity of variance was used to determine if the groups had equivalent variances (Snedecor and Cochran, 1971) . If the variances were equal, the testing for significance was done using a parametric method, a standard one-way ANOVA. If significant differences among the means were indicated, Dunnett's test was used (Dunnett, 1964) to determine which treatment groups differed from controls. If the groups did not have equivalent variances, the test of equality of means was performed using the KruskallWallis test (Hollander and Wolfe, 1973) . If the means were different, Dunn's summed rank test was used to determine which treatment groups differ significantly from control (Hollander and Wolfe, 1973) . The test for equal variance was conducted at the 1% level of significance. All other tests were conducted at the 5 and 1% levels of significance.
The survival analysis used two methods: (1) the WeibuU estimate of median survival and (2) the Kaplan-Meier method with a comparison between groups using both the generalized Kruskal-Wallis test and Cox's test (Kaplan and Meier, 1958) .
Three methods of statistical analyses were used to assess tumor incidence data in the chronic study: (1) life table analyses (Mantel and Haenszel, 1959; Cox, 1972; Tarone, 1975) , (2) incidental tumor analysis (Haseman, 1984) , and (3) unadjusted analysis for linear dose response. The last method consists of a pairwise comparison of each dose group with the control by the Fisher exact test and a test for linear trend (Armitage, 1971; Gart et al., 1979) .
RESULTS

Daily Dose Estimation
The daily dose of DINP was calculated from the body weight and diet consumption data using the concentrations of DINP in the diet. The mean daily intakes of DINP over 2 years for male rats were 15, 152, and 307 mg/kg/day corresponding to dose levels of 0.03, 0.3, and 0.6 wt%, respectively. For female rats, the mean daily intakes were 18, 184, and 375 mg/kg/day, respectively.
Body Weights
Mean body weights by sex and group after 6, 12, 18, and 24 months of treatment are summarized in Table 1 . When compared with controls, the high-dose males had a statistically significant, dose-related decrease in body weight at 12 months of treatment and continued to display this decrease at 18 and 24 months of treatment. The mean body weights for the high-dose-group males were approximately 4 to 7% lower than corresponding controls. There were no statistically significant changes in females. In general, the treated females weighed slightly more than the control animals until approximately the last 6 months of the study, where they displayed a slight decrease in body weight.
Survival
Survival data are summarized in Table 2 . Survival was greater than 60% in all groups at study termination. Survival in the control rat groups was 75-80% and was similar to that observed in chronic feeding studies in F344 rats sponsored by the National Toxicology Program (NTP) (Cameron et al, 1985; Solleveld et al., 1984) . A slight decrease in overall survival was noted in the mid-and high-dose groups of both sexes compared to controls, but whether or not this decrease was statistically significant depended on the statistical method employed. No difference was observed using the Weibull technique. The Cox and generalized KruskallWallis tests indicated a significant difference in survival in mid-and high-dose female rats.
The incidence of clinical in-life observations was relatively low throughout the 24-month test period. The most frequently noted observation included alopecia and scabs on the skin which appeared unrelated to treatment.
Organ Weights
Relative organ weights for the liver, kidney, and spleen are summarized in Tables 3 and 4 for males and females, respectively. Both males and females of the mid-and highdose groups had a statistically significant, dose-related increase in relative kidney and liver weights throughout most of the treatment period; the absolute liver and kidney weights demonstrated a similar trend (data not shown). At study termination, the mid-and high-dose males and high-dose females exhibited a statistically significant increase in absolute and relative spleen weight compared to controls. Absolute and relative adrenal weights were slightly but significantly increased in high-dose female rats after 6 and 12 months of treatment. In addition, at study termination, relative but not absolute adrenal weights were slightly but significantly increased in high-dose rats of both sexes. No treatment-related changes were observed in the absolute or relative organ weights for ovaries, testes, brain, heart, or thyroid/ parathyroid.
Hematology
In general, the mean hematologic values were within normal limits for both sexes treated with DINP for 6, 12, and " Statistically significant from control group mean at 5% level.
mid-and high-dose males and females compared to control values. However, only the high-dose males showed a statistically significant decrease in RBC, hemoglobin, and hematocrit compared with controls. The high-dose males and females also exhibited an increased frequency of occurrence of nucleated RBC, polychromatophilic red cells, and reticulocytes when compared with control animals.
Serum Chemistry
An evaluation of the serum chemistry values at 6, 12, and 18 months revealed no remarkable findings. Some parame- ters were statistically increased (BUN, A/G ratio, creatinine) but were judged unlikely to be of biological significance due to a lack of dose response. The following parameters usually associated with liver function were weakly increased in the mid-and high-dose males at all time intervals in the study: alkaline phosphatase, SGOT, and SGPT (see Table 6 ). In general, these responses were statistically significant and may be related to treatment. No statistically significant effects were observed on total bilirubin. The results of the female serum chemistry profile revealed no statistically significant treatment-related effects on liver function parameters.
Urine Chemistry
The qualitative urine chemistry parameters were nonremarkable at all time intervals for both males and females. The quantitative urine chemistry parameters were unaffected in females at all time intervals, but the males showed slight but statistically significant changes in some of the parameters throughout the study. The high-dose males exhibited increased urine volumes when compared to controls at all time intervals. In the mid-or high-dose males, potassium and glucose showed a statistically significant increase at 6, 12, and 18 months, but not at 24 months. A statistically significant increase in excretion of renal epithelial cells was noted in high-dose males at 6 months but not at later treatment periods.
Gross Effects at Necropsy
No grossly observable and treatment-related abnormalities were apparent at each of the interim sacrifices. At study termination, however, the mid-and high-dose males and high-dose females exhibited an increased incidence of splenic enlargement when compared with control animals. 
Morphological Examination of Liver
Ultrastructural examination of liver specimens from representative rats of each sex from the four groups did not reveal any treatment-related peroxisomal proliferation.
Histopathology (6, 12, and 18 Months)
No treatment-related effects on tissues were observed in rats sacrificed after 6 and 12 months of treatment. At the 18-month sacrifice, there were no treatment-related neoplastic lesions but nonneoplastic lesions were observed in the liver and kidney of treated rats. Minimal to slight centrilobular to midzonal hepatocellular enlargement was present in 9/10 male and 10/10 female rats treated with 0.6% DINP; this effect was absent in controls. In the kidneys, a minimal increase in tubular cell pigment was noted in the tubular epithelium of high-dose male rats.
Histopathology (24 Months)
The most common causes of the unscheduled deaths and/ or morbidity were mononuclear cell leukemia (MNCL) and, to a lesser extent, pituitary neoplasia. Tubular cell pigmentation in the kidney was increased in severity in animals with advanced MNCL. 
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11.0 7 * Nineteen to 20 rats were examined at each concentration. * Statistically significant from control group mean at 5% level. ' Statistically significant from control group mean at 1 % level.
At terminal sacrifice, a variety of spontaneous disease lesions and incidental findings of the expected type and incidence occurred in control and treated rats without relationship to treatment with the exception of liver lesions and MNCL. Nonneoplastic lesions in the liver are summarized in Table 7 . Slight centrilobular to midzonal hepatocellular enlargement was present in a small number of rats and was comparable to the findings at the 18-month sacrifice. A slight increase in MNCL was noted in the mid-and high-dose rats of both sexes. Table 8 summarizes selected neoplastic lesions (MNCL, liver, kidney, and testes) in rats. MNCL occurred at a statistically significant increased incidence in the mid-and high-dose groups of both sexes when compared with the control groups and with a significantly increasing trend over time (Table 8 ). In many of the rats, the MNCL was very early and limited to an increase in mononuclear cells in the hepatic sinusoids. The MNCL was associated with a variety of hepatic alterations (nonneoplastic lesions) " Group size at 6, 12, and 18 months was 9-10 rats examined for each parameter. * Group size at 24 months was 20 rats examined for each parameter. ' Statistically significant from control group mean at 5% level. "Statistically significant from control group mean at 1% level. which included regenerative nodules, focal necrosis, spongiosis hepatis, and ' 'hepatopathy associated with leukemia'' (see Table 7 ). Spongiosis hepatis is a liver lesion of the perisinusoidal cells, and a number of pathologists may classify this lesion as cystic degeneration.
DINP produced no treatment-related preneoplastic or neoplastic lesions of the liver (Table 8 ). The incidence of preneoplastic and neoplastic liver lesions in control F344 rats was of similar incidence as reported by other investigators (Popp et al, 1985) .
DINP also failed to produce any clear treatment-related effects on the kidneys. Kidney sections revealed chronic progressive nephropathy in most of the rats which was not increased in severity by treatment. Renal neoplasms were present in three mid-dose and two high-dose male rats (Table  8) which consisted of two tumor types: transitional cell carcinomas and tubular cell carcinomas. According to the NTP guidelines (McConnell et al, 1986; NTP, 1984) , these histogenic types should not be combined for carcinogenic evaluation. Each of these tumor types was not statistically signifi- cant when compared to control animals. In addition, there was no evidence of any treatment-related preneoplastic renal lesions (Table 8) .
DINP also failed to produce any treatment-related effects on the testes (Table 8) . As expected, the control animals displayed a high incidence of testicular tumors. DISCUSSION DINP was not a liver carcinogen in F344 rats at a dietary level up to 0.6% DINP. Morphologic evaluations also indicated that hepatic peroxisome proliferation was not induced in the chronic study. This result is consistent with the hypothesis that doses which fail to produce peroxisome induction are unlikely to show a liver cancer effect (Ashby et al, 1994) . A number of structurally different compounds demonstrated to produce a marked increase in hepatic peroxisomes and liver cancer in rodents led to the hypothesis that hepatic peroxisome proliferation may be involved in the hepatocarcinogenic action of these compounds (Reddy et al, 1983) . Data on another phthalate ester, di-2-ethylhexyl phthalate (DEHP), are consistent with this theory. DEHP at dietary levels of 0.6 and 1.2% produced hepatic peroxisome proliferation and liver tumors in F344 rats (BIBRA, 1985a; Cattley et al, 1987; NTP, 1982) . No treatment-related increase in liver tumors was observed in female F344 rats at 0.1% DEHP, a dose which produced negligible effects on hepatic peroxisome induction (Cattley et al, 1987) .
The increases of liver and kidney weights (absolute and relative) in this study were of a similar magnitude as those observed in the 13-week dietary study of DINP at the same dietary dose levels (Bird et al, 1986) . The increases in liver weight at 3, 6, 12, or 18 months of treatment were not accompanied by any histopathologic lesions in the liver. The liver enlargement induced by DINP at high dietary doses (1.0 and 2.0%) is associated with a proliferation of smooth endoplasmic reticulum (SER) and microsomal enzyme induction as well as proliferation of peroxisomes and peroxisomal enzyme induction (Bird et al, 1987; BIBRA, 1985b) . In the 13-week dietary study, the morphological evaluation of the liver revealed a weak increase in peroxisome induction at 0.6% DINP (approximate dose of 450 mg/kg/day) with clear evidence of peroxisomal induction at dietary doses of 1.0% DINP or greater. In this 2-year study, there appeared to be no evidence for treatment-related peroxisome induction at dietary levels up to 0.6% DINP (approximate dose of 340 mg/kg/day) based on electron microscopic evaluation of representative rats of each sex from all dose groups. This apparent lack of peroxisome induction, as measured by morphological methods, is consistent with biochemical data on peroxisome induction from other studies. F344 rats fed 3 weeks with 0.6% DINP (approximate dose of 600 mg/kg/ day) showed no statistically significant effects on the specific and sensitive peroxisome marker cyanide-insensitive palmitoyl CoA oxidation (BIBRA, 1985b) , whereas clear evidence of peroxisome induction was observed with 1.2 and 2.5% dietary DINP (approximate doses of 1190 and 2240 mg/kg/ day, respectively). In this same 3-week study, 0.6% DINP produced a significant increase in two microsomal enzymes: 11-and 12-hydroxylases of lauric acid (BIBRA, 1985b) . The liver enlargement induced by dietary DINP during periods up to 18 months appears to represent an adaptive rather than a toxic response based on two considerations: (1) absence of histopathological lesions and (2) clinical chemistry tests for the liver were typically in the normal range of values.
The increase in kidney weight in the subchronic and chronic studies was associated with some histopathological changes or effects in urinalysis parameters of male rats (i.e., decrease in osmolality and increases in volume, glucose, protein, and REC). In the 13-week study (Bird et al, 1986) , the histopathological effects consisted of nephrosis and tubular regeneration which were evident at the mid-and highdose groups (0.3 and 0.6% DINP). In the chronic study, these histopathological effects were not observed to be treatment related perhaps because of the confounding high incidence of spontaneous kidney lesions in aged rats (Peter et al, 1986) .
At study termination, DINP produced statistically significant increases in MNCL in the mid-and high-dose groups of F344 rats. MNCL in F344 rats is associated with secondary effects on organ weights (splenic enlargement), hematological parameters (decreases in hemoglobin and hematocrit), clinical chemistry parameters (liver function indices such as ALT, AST, bilirubin, etc.), as well as liver lesions such as necrosis (Stromberg et al, 1983a,b,c) .
A review of the literature and our own data collectively suggest that the increase of MNCL in F344 rats is a common finding in aging F344 rats and that the increased incidence in rats treated with DINP is not relevant to humans.
The NTP has observed that tumor types, such as MNCL, which have a high spontaneous incidence in aging F344 rats, are most likely to contribute to false positives in carcinogenicity evaluations (Maronpot, 1985) . MNCL occurs to a high and variable extent (10-72%) in untreated aged F344 rats (Haseman et al, 1989; Maronpot, 1980) . The highest historical rate reported for untreated male rats was 72% which is above the highest incidence (64%) following DINP treatment. The highest historical rate reported in untreated female rats was 52% which is of similar or higher incidence observed in mid-and high-DINP-dose-treated female rats (38 and 54%, respectively). Although approximately 10% of chemicals examined in the NTP cancer bioassays produced a statistically significant increase in MNCL in F344 rats (Huff et al, 1991) , MNCL was not judged to be biologically significant for all of these chemicals after a weight-of-evidence evaluation (ECETOC, 1990; Mennear, 1994; NTP, 1990; Squire, 1989; Whysner etal., 1995) . For example, tris-(2-chloroethyl) phosphate (TRCP), another ester chemical, produced a statistically significant increase in MNCL of both sexes but the incidences in treated groups were within the historical control range (NTP, 1990) . In its evaluation of TRCP, NTP (1990) stated that "These marginal increases in male and female rats were not considered to be clearly related to administration of TRCP." NTP noted that sound scientific judgment is needed to guard against statistical false positives (Haseman, 1990) .
Another important consideration is that MNCL in F344 rats is not a reproducible effect and the incidence is influenced by a number of variables in F344 rats (e.g., pathologist, diet, spleen damage, etc.) (Elwell etal, 1996; Haseman et al, 1984 Haseman et al, , 1989 Haseman et al, , 1992 Thurman et til, 1994) . Several different chemical studies in F344 rats have indicated that the occurrence and incidence of MNCL are not reproducible; these chemical studies include butyl benzyl phthalate (NTP, 1995) , olestra (Wood et al, 1991) , hydroquinone (Whysner etal, 1995) , and acetaminophen (NTP, 1993) . Of note, NTP conducted two dietary studies on butyl benzyl phthalate at identical doses separated by a number of years with the early study showing some evidence of MNCL while the later studies showed no treatment-related effects (NTP, 1995) . Further, acetaminophen failed to produce an increase in MNCL in Sprague-Dawley rats, a rat strain with a low spontaneous incidence of MNCL (Gopinath, 1994; Sher, 1982) .
DINP did not show a profound effect on tumor latency regarding MNCL, which is another consideration in evaluating tumors with a high and variable spontaneous rate in aged animals. Enomoto et al. (1990) suggested that a 78-week study on chemicals may be useful to evaluate whether MNCL is a genuine effect in F344 rats. F344 rats treated with DINP (6, 12, and 18 months) failed to show any treatment-related effects on MNCL or related associated markers of this tumor such as spleen weight increase or bone marrow changes.
Another important consideration is whether MNCL in F344 rats is an appropriate animal model for man. The prevailing data indicate that the histogenic tumor type (MNCL) in F344 rats does not occur in humans (Swaen and Van Heerde, 1987) . Moreover, this leukemia in F344 rats appears to arise from the spleen, but this does not appear to be the case for humans where leukemia originates from affects on the bone marrow (Iatropoulos, 1983) .
Thus, these considerations suggest that MNCL is a common finding in aging F344 rats and that increased incidence of MNCL is not relevant to humans.
In conclusion, these studies indicate that DINP has a low potential for chronic toxicity and carcinogenicity in F344 rats. Organ weights of liver and kidney were increased at the mid and high doses. There was no clear evidence of any carcinogenic effects except for a marginal increase in the incidence of MNCL in mid-and high-dose rats which is not considered a relevant risk for humans.
